Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX™ in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy

NCT01222624 is registered in ClinicalTrials.gov with Glycotope GmbH as lead sponsor.

NCT NCT01222624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01222624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX™ in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy
Lead sponsor
Glycotope GmbH
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2009
Completion date
May 31, 2013
Enrollment
74 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors